Amgen Inc.’s stock fell 3.3% Tuesday to put it on track for its biggest one-day percentage decline in more than a year, after the company’s better-than-expected quarterly earnings were offset by comments on its obesity pipeline that suggested a longer wait than some were expecting.
On its call, Amgen AMGN, -3.48% said it expects initial data from a Phase 1 trial of its AMG 786 obesity treatment to come in the first half of 2024. It has completed enrolment in a Phase 2 trial of its AMG 133 treatment with top-line data expected in late 2024.
The company expects to bring a suite of preclinical obesity assets forward “over the next few years,” he added. Amgen’s intent is to play the long game, “given that this is one of the major public health challenges of the 21st century.” headtopics.com
The biotech, which closed its $27.8 billion acquisition of Horizon Therapeutics plc on October 6, posted net income of $1.730 billion, or $3.22 a share, for the quarter, down from $2.143 billion, or $3.98 a share, in the year-earlier period.Revenue climbed to $6.903 billion from $6.652 billion, close to the $6.923 billion FactSet consensus.
Sales of the company’s Enbrel, which is used to treat autoimmune diseases, fell 6% in the third quarter3. Repatha, a treatment for cholesterol, saw sales climb 31%, while osteoporosis treatment Prolio saw sales rise 14%. headtopics.com
Why Utah hunters may have to report all deer, elk harvests beginning in 2024Utah wildlife officials are exploring a new rule that would require hunters to report all deer and elk harvested during the general season hunts beginning next year. Read more ⮕
Iowa offensive coordinator Brian Ferentz won’t return in 2024Iowa offensive coordinator Brian Ferentz, the son of longtime coach Kirk Ferentz whose contract amid the offense’s historic struggles drew national attention, will not return for the 2024 season, the school announced in a Monday statement. Read more ⮕
Lawyers argue whether Constitution’s ‘insurrection’ clause blocks Trump from 2024 ballotA court in Colorado is hearing arguments using the Constitution’s ‘insurrection’ clause to block Trump from a 2024 election bid. Read more ⮕
Boebert claims ‘lawfare’ is Democrats’ choice of attack for 2024Misty Severi is a breaking news reporter for the Washington Examiner. She has a particular interest in the United States military, European and international politics, and U.S. and European history. Read more ⮕
Lawyers argue whether Constitution’s ‘insurrection’ clause blocks Donald Trump from 2024 ballotTestimony in a lawsuit on Monday began with details about the Jan. 6 attack that was intended to stop Congress from certifying Democrat Joe Biden’s election win and included first-hand accounts from some who were there. Read more ⮕
New Halloween-themed runs, including kids’ races, will dash into Disneyland in 2024The dress-up delights shall debut at the Anaheim theme parks in early September. Read more ⮕